GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
| 
                                                                Synonyms: Compound A [WO2022174269A1] | KT474
                                 Compound class: 
                                                            Synthetic organic
                                 
                                    
                                        Comment: KT-474 is a PROTAC degrader of interleukin 1 receptor associated kinase 4 (IRAK4). It is in Kymera Therapeutics' pipeline and is initially being developed for potential to treat the autoimmune conditions atopic dermatitis and hidradenitis suppurativa [2]. A thalidomide analogue moiety is employed to direct the bound IRAK4 to the ubiquitin-proteasome pathway via the thalidomide-cereblon interaction.
                                    
                                 | 
 | |||||||||||||||||||||||||||||||||||
| Bioactivity Comments | 
| KT-474 (I-417) inhibits IRAK4-mediated IL-6 secretion in R848-stimulated human PBMC with an IC50 <1 nM [1] |